新辅助治疗在交界可切除胰腺癌中的结局:实践与证据演变时代的单中心分析
该研究基于印度塔塔纪念中心2007-2019年前瞻性数据库的201例交界可切除胰腺癌患者,比较 upfront 手术(UPS)与新辅助治疗(NAT)的围手术期及长期结局。NAT组148例中31.8%出现进展,切除率显著低于UPS组(42.56% vs 75.47%),但R0切除率显著更高(74.6% vs 42.5%);意向治疗分析中位OS无显著差异(15 vs 18个月),但NAT组完成治疗者OS显著更优(34 vs 22个月)。
要点
- NAT组31.8%出现疾病进展,切除率显著低于UPS组(42.56% vs 75.47%)。
- NAT组R0切除率显著优于UPS组(74.6% vs 42.5%),并显著降低pT分期、淋巴结阳性率及神经侵犯。
- 意向治疗分析中位OS无显著差异(15 vs 18个月),但NAT组完成治疗者OS显著更优(34 vs 22个月)。
核心结论
- BRPC患者接受NAT的进展率为31.8%,NAT与显著病理降期、R0切除率提高及切除患者生存改善相关。
研究设计与样本
- 基于印度塔塔纪念中心2007-2019年前瞻性维护数据库,分析201例连续交界可切除胰腺癌患者,比较NAT与UPS的围手术期及长期结局。
主要发现
- NAT组148例,UPS组53例;NAT组47例(31.8%)出现进展,总切除103例(51.24%)。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neoadjuvant therapy (NAT) is increasingly being used in the management of borderline resectable pancreatic cancer (BRPC). We compared the outcomes of patients with BRPC treated either with upfront surgery (UPS) or NAT to assess whether increased use of NAT has helped improve perioperative and long-term outcomes. METHODS: Prospectively maintained database of 201 consecutive patients with BRPC treated at Tata Memorial Center, India, from 2007-2019 was analyzed. RESULTS: NAT was offered to 148 patients and 53 were planned for UPS. Progression on NAT was seen in 47 (31.8%) patients. Resection was performed in 103 patients (51.24%). The resection rate was significantly lower after NAT as compared with upfront explorations (42.56% vs 75.47%, P = .00) however, R0 resection rate after NAT was significantly better (74.6% vs 42.5%, P = .001). NAT group showed a significant decrease in the pT stage (P = .004), node positivity (60%-31.7%, P = .005%), and perineural invasion (70%-41.6% P = .026). There was no significant difference in the median overall survival (OS) of patients offered NAT versus UPS on an intention-to-treat basis (15 vs 18 months P = .431). However, OS (22 vs 19 months, P = .205) and disease-free survival (DFS) (16 vs 11 months, P = .135) were higher for resected patients in the NAT group and OS was significantly superior in patients completing the course of treatment (34 vs 22 months, P = .010) CONCLUSION: The progression rate with NAT in patients with BPRC was 31.8%. NAT was associated with significant pathologic downstaging, improvement in R0 resection rate, and survival in resected patients.
引用
- Chaudhari VA, Mitra A, Gupta V, et al. Neoadjuvant therapy in borderline resectable pancreatic cancer: Outcomes in the era of changing practices and evolving evidence. Surgery. 2021. PMID: 34922745. doi:10.1016/j.surg.2021.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。